PMID- 27210868
OWN - NLM
STAT- MEDLINE
DCOM- 20170130
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 37
IP  - 5
DP  - 2016 May 14
TI  - [Clinical features and prognostic analysis of high-risk acute promyelocytic 
      leukemia patients].
PG  - 360-5
LID - 10.3760/cma.j.issn.0253-2727.2016.05.002 [doi]
AB  - OBJECTIVE: To investigate the clinical features and outcomes of high-risk acute 
      promyelocytic leukemia (APL) patients. METHODS: A retrospective analysis was 
      conducted to compare the clinical characteristics and prognosis of 118 high-risk 
      APL patients (WBC>/=10 x 10(9)/L) and 234 low and intermedia-risk patients (WBC 
      <10x10(9)/L) from January 2003 to April 2015, who were treated in the First 
      Affiliated Hospital of Zhejiang University and Yinzhou People's Hospital 
      affiliated to Medical College of Ningbo University. RESULTS: The initial platelet 
      counts of high-risk APL were significantly lower than that of low and 
      intermediate-risk groups (P=0.003); the major type of PML-RARalpha isoforms in 
      high-risk patients was short-form (51.8% vs 28.2%, P <0.001); the early death 
      (ED) rate of high-risk patients was higher than low and intermedia-risk patients 
      (20.3% vs 2.6%, P<0.001); in contrast, the complete remission (CR) rate and 5 
      years estimated overall survival (OS) rate of the former were lower than the 
      latter (76.3% vs 94.9%, P <0.001; 74.2% vs 93.7%, P <0.001). However, the CR rate 
      (P=0.682) and 5 years estimated OS rate (P=0.481) did not have difference when 
      the ED patients were excluded. The 5 years estimated relapse-free survival (RFS) 
      and central nervous system (CNS) relapse were 82.7%, 9.4%, respectively, which 
      were lower than low and intermediate-risk groups (87.8%, 1.4% ) with statistic 
      difference (P=0.048, 0.002). High-dose cytarabine and intrathecal chemotherapy 
      may reduce the risk of CNS relapse. CONCLUSION: The outcomes of high-risk APL 
      patients were worse than low and intermediate-risk group owing to the high ED 
      rate and CNS relapse, it was important to decrease the ED rate and emphasis the 
      CNS prophylaxis for high-risk APL patients.
FAU - Pei, R Z
AU  - Pei RZ
FAU - Si, T
AU  - Si T
FAU - Lu, Y
AU  - Lu Y
FAU - Zhang, P S
AU  - Zhang PS
FAU - Liu, X H
AU  - Liu XH
FAU - Ye, P P
AU  - Ye PP
FAU - Chen, D
AU  - Chen D
FAU - Du, X H
AU  - Du XH
FAU - Ma, J X
AU  - Ma JX
FAU - Jin, J
AU  - Jin J
AD  - Department & Institute of Hematology, The First Affiliated Hospital of Zhejiang 
      University, The Key Laboratory of Hematologic Tumor (Diagnose and Treatment) of 
      Zhejiang Province, Hangzhou 310003, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Protein Isoforms)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 04079A1RDZ (Cytarabine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Cytarabine/therapeutic use
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*diagnosis
MH  - Leukocyte Count
MH  - Oncogene Proteins, Fusion/metabolism
MH  - Platelet Count
MH  - Prognosis
MH  - Protein Isoforms/metabolism
MH  - Recurrence
MH  - Remission Induction
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC7348312
EDAT- 2016/05/24 06:00
MHDA- 2017/01/31 06:00
PMCR- 2016/05/01
CRDT- 2016/05/24 06:00
PHST- 2016/05/24 06:00 [entrez]
PHST- 2016/05/24 06:00 [pubmed]
PHST- 2017/01/31 06:00 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - cjh-37-05-360 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2016.05.002 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2016 May 14;37(5):360-5. doi: 
      10.3760/cma.j.issn.0253-2727.2016.05.002.